One interesting ongoing study is the INFORM2‐NivEnt,35 which combines ICI treatment with an HDAC‐inhibitor in relapsed pediatric cancer patients, in four biomarker defined groups, one of which is based on PD‐L1 expression. Here, HDAC9 is linked to cancer.